Together, the translational and clinical data converge on a compelling hypothesis: SGLT2 overexpression may be both a marker and a driver of adverse myocardial remodeling in AS, and pharmacologic inhibition of this pathway may serve as a strategy to attenuate disease progression and improve outcomes across the AS continuum. Here, SLC5A2 is linked to aortic stenosis.